ALSO NOTED: Bayer inks $344M deal for Possis; Indian drug makers not hungry for deals;

> Bayer's Medrad unit has agreed to pay about $344 million for Possis Medical, a 36 percent premium over the company's closing stock price on Friday. Report

> Indian pharma companies are shy of making any overseas acquisitions in 2008 as they continue to work through big-ticket takeovers made in 2006, market observers say. Report

> Hospital meds company Maelor is launching Aloxi, a new generation anti-emetic for use in chemo patients, in the U.K. Report

> India's Biocon is buying a 70 percent stake in the German pharma AxiCorp. Report

> In another display of monoclonal antibodies' appeal to drug developers, Maryland-based Humab Genome Sciences announced that it will team up with Xencor on drug development. Report

> According to public records, Millennium Pharmaceuticals spent $1.3 million in 2007 lobbying the federal government on patent reform and biotech drug regulation. Report

> Memory Pharmaceuticals' CEO Jim Sulat has announced plans to step down from the position for personal reasons. Report

> RNAi trailblazer Alnylam has published a paper in the journal Human Molecular Genetics that details RNAi's ability to silence a gene implicated in early onset torsion dystonia. Report

And Finally... We'd be healthier if we all got a little medieval on our diets. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.